CeraVe is an American dermo-cosmetic brand that offers a complete line of expert-developed skincare products designed to restore and maintain the skin's natural barrier. Founded in 2005 and now owned by the L'Oréal Group, CeraVe is distinguished by its core philosophy: all formulas are enriched with a unique blend of three essential, skin-identical ceramides (lipids that make up 50% of the skin barrier). These products utilize patented MultiVesicular Emulsion (MVE) Technology to ensure the controlled, continuous release of moisturizing ingredients for up to 24 hours, providing long-lasting hydration and therapeutic results for conditions such as eczema and acne.
CeraVe's heritage is rooted in a scientific discovery made in 2005: a compromised skin barrier is a common factor in many skin conditions, including dryness, acne, and psoriasis. Recognizing this unmet need, a group of expert dermatologists and researchers in the U.S. collaborated to develop a new standard of therapeutic, yet accessible, skincare. The brand launched in 2006 with just three core products—a Moisturizing Cream, Moisturizing Lotion, and Hydrating Cleanser—all centered around replenishing essential ceramides and using MVE technology. The "Cera" in the name stands for ceramides, and "Ve" for the MVE delivery technology, cementing the brand's foundation in science-backed solutions that were initially developed for use in exam rooms.
CeraVe was founded in 2005 by a group of dermatologists and researchers. A key figure among the co-founders isTom Allison, who has been noted as CeraVe's Senior VP of Global Professional Sales, Marketing, and Strategy and a co-founder. Prior to founding CeraVe, Allison had 20 years of experience in the dermatology field, where he built relationships with dermatologists and noticed the struggles patients faced in finding effective, safe, and affordable products for various skin conditions. The formulations were developed in close collaboration with these leading dermatologists to ensure efficacy and safety, and the brand was initially part of the pharmaceutical company Valeant Pharmaceuticals International before being acquired by L'Oréal in 2017.
